Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV

Pharmacotherapy

Volumn 20, Issue 9 I, 2000, Pages 1066-1071

  Penzak, S R ^a   Chuck, S K ^a   Stajich, G V ^a  

^a MERCER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; LIVER DYSFUNCTION; MALE; MYALGIA; RETROSPECTIVE STUDY;

EID: 0033813398     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.13.1066.35033     Document Type: Article

References (26)

1. Protease inhibitor-induced lipodystrophy
2. Lipodystrophy related to NRT inhibitors in HAART therapy
3. Case report of lipodystrophy observations in patients naive of protease inhibitor treatment, aquitaine cohort
4. Incidence of fat tissue abnormalities in protease inhibitor-naive patients treated with NRTI combinations
5. Cumulative risk for developing hyperlipidemia in HIV-infected patients treated with protease inhibitors
6. Lipid abnormalities associated with use of protease inhibitors: Prevalence, clinical sequelae and treatment
7. Do protease inhibitors increase the risk for coronary heart disease among HIV positive patients?
8. No association observed between indinavir therapy for HIV/AIDS and myocardial infarction in 4 clinical trials with 2,825 subjects
9. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities
10. Atorvastatin for protease inhibitor-related hyperlipidaemia
11. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4S)
12. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
13. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
14. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels
15. Second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel II)
16. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia
17. Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1+ patients
18. A multi-center, randomized, open-label, comparative trial of the clinical benefit of switching the protease inhibitor (PI) by nevirapine (NVP) in HAART-experienced patients suffering from lipodystrophy (LD)
19. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine
20. Reversal of hyperlipidemia in patients switching therapy to nelfinavir
21. Reversibility of protease inhibitor (PI) lipodystrophy syndrome on stopping PIs or switching to nelfinavir
22. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar?
23. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
24. Pharmacokinetic interactions between protease inhibitors and selected HMG-CoA reductase inhibitors
25. Fluvastatin: A review of its use in lipid disorders
26. Rational Assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions